The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions

Nature Medicine

Volumn 10, Issue 7, 2004, Pages 685-692

  Rogawski, Michael A ^a   Löscher, Wolfgang ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM ION; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SODIUM ION; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ALCOHOL WITHDRAWAL; ANXIETY DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL PATHWAY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSTONIA; GENE OVEREXPRESSION; HUMAN; INSOMNIA; MIGRAINE; MOOD DISORDER; MYOCLONUS; MYOKYMIA; NERVE CELL PLASTICITY; NERVE INJURY; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; PRIORITY JOURNAL; REGULATORY MECHANISM; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRIGEMINUS NEURALGIA;

ANTICONVULSANTS; BIPOLAR DISORDER; CALCIUM CHANNELS; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR DISEASES; PAIN; SCHIZOPHRENIA; SODIUM CHANNELS;

EID: 3142774111     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1074     Document Type: Review

References (114)

1. Löscher, W. & Schmidt, D. New horizons in the development of antiepileptic drugs. Epilepsy Res. 50, 3-16 (2002).
2. Fromm, G.H. Antiepileptic actions of carbamazepine. in Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders (eds. Faingold, C.L. & Fromm, G.H.) 425-436 (CRC Press, Boca Raton, Florida, USA, 1992).
3. Silberstein, S.D. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 41 (suppl. 1), S11-S17 (2001).
4. Ottman, R. & Lipton, R.B. Comorbidity of migraine and epilepsy. Neurology 44, 2105-2110 (1994).
5. Rogawski, M.A. & Löscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5, 553-564 (2004).
6. Rudolph, U. & Möhler, H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol. 44, 475-498 (2004).
7. - current, J. Neurosci. 13, 3211-3221 (1993).
8. Pollack, M.H., Matthews, J. & Scott, E.L. Gabapentin as a potential treatment for anxiety disorders. Am. J. Psychiatry 155, 992-993 (1998).
9. Pande, A.C. et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 19, 341-348 (1999).
10. de-Paris, F. et al. Effects of gabapentin on anxiety induced by simulated public speaking. J. Psychopharmacol. 17, 184-188 (2003).
11. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 55 (suppl. 1), S41-S46 (2000).
12. Eisenberg, E., Alon, N., Ishay, A., Daoud, D. & Yarnitsky, D. Lamotrigine in the treatment of painful diabetic neuropathy. Eur. J. Neurol. 5, 167-173 (1998).
13. Nicholson, B. Gabapentin use in neuropathic pain syndromes. Acta Neurol. Scand. 101, 359-371 (2000).
14. Pappagallo, M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin. Ther. 25, 2506-2538 (2003).
15. Rozen, T.D. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache 41 (suppl. 1), S25-S32 (2001).
16. Beydoun, A. & Backonja, M.M. Mechanistic stratification of antineuralgic agents. J. Pain Symptom. Manage. 25, S18-S30 (2003).
17. Dib-Hajj, S.D. et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83, 591-600 (1999).
18. Kim, C.H., Oh, Y., Chung, J.M. & Chung, K. The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res. Mol. Brain Res. 95, 153-161 (2001).
19. Craner, M.J., Klein, J.P., Renganathan, M., Black, J.A. & Waxman, S.G. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann. Neurol. 52, 786-792 (2002).
20. Abe, M., Kurihara, T., Han, W., Shinomiya, K. & Tanabe, T. Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine 27, 1517-1524 (2002).
21. v1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 23, 158-166 (2003).
22. Hains, B.C. et al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23, 8881-8892 (2003).
23. Cummins, T.R. et al. Nav1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21, 5952-5961 (2001).
24. Novakovic, S.D. et al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J. Neurosci. 18, 2174-2187 (1998).
25. v1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol. (Lond). 550, 921-926 (2003).
26. Shah, B.S. et al. β3, a novel auxiliary subunit for the voltage-gated sodium channel, is expressed preferentially in sensory neurons and is upregulated in the chronic constriction injury model of neuropathic pain. Eur. J. Neurosci. 12, 3985-3990 (2000).
27. Shah, B.S. et al. β3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci. Lett. 309, 1-4 (2001).
28. Bartolomei, F. et al. Changes in the mRNAs encoding subtypes I, II and III sodium channel a subunits following kainate-induced seizures in rat brain. J. Neurocytol. 26, 667-678 (1997).
29. Aronica, E. et al. Induction of neonatal sodium channel II and III α-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus. Eur. J. Neurosci. 13, 1261-1266 (2001).
30. + channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 119, 323-333 (2003).
31. Whitaker, W.R. et al. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus. Neuroscience 106, 275-285 (2001).
32. Todorovic, S.M., Rastogi, A.J. & Jevtovic-Todorovic, V. Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. Brit. J. Pharmacol. 140, 255-260 (2003).
33. Rizzo, M.A. Successful treatment of painful traumatic mononeuropathy with carbamazepine: insights into a possible molecular pain mechanism. J. Neurol. Sci. 152, 103-106 (1997).
34. Burchiel, K.J. Carbamazepine inhibits spontaneous activity in experimental neuromas. Exp. Neurol. 102, 249-253 (1988).
35. Herrero, J.F., Laird, J.M. & Lopez-Garcia, J.A. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog. Neurobiol. 61, 169-203 (2000).
36. Chapman, V., Wildman, M.A. & Dickenson, A.H. Distinct electrophysiological effects of two spinally administered membrane stabilising drugs, bupivacaine and lamotrigine. Pain 71, 285-295 (1997).
37. Murakami, M. et al. Pain perception in mice lackingthe β3 subunit of voltage-activated calcium channels. J. Biol. Chem. 277, 40342-40351 (2002).
38. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 147, 456-463 (2002).
39. Newton, R.A., Bingham, S., Case, P.C., Sanger, G.J. & Lawson, S.N. Dorsal root ganglion neurons show increased expression of the calcium channel α2δ-1 subunit following partial sciatic nerve injury. Brain Res. Mol. Brain Res. 95, 1-8 (2001).
40. Luo, Z.D. et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci. 21, 1868-1875 (2001).
41. Pan, H.-L., Eisenach, J.C. & Chen, S.-R. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J. Pharmacol. Exp. Ther. 288, 1026-1030 (1999).
42. Stanfa, L.C., Singh, L., Williams, R.G. & Dickenson, A.H. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. NeuroReport 8, 587-590 (1997).
43. Patel, M.K., Gonzalez, M.I., Bramwell, S., Pinnock, R.D. & Lee, K. Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord. Br. J. Pharmacol. 130, 1731-1734 (2000).
44. Luo, Z.D. et al. Injury type-specific calcium channel α2δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J. Pharmacol. Exp. Ther. 303, 1199-1205 (2002).
45. Shimoyama, M., Shimoyama, N. & Hori, Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85, 405-414 (2000).
46. Field, M.J., Hughes, J. & Singh, L. (2000) Further evidence for the role of the α2δ subunit of voltage dependent calcium channels in models of neuropathic pain. Brit. J. Pharmacol. 131, 282-286 (2000)
47. Todorovic, S.M. et al. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron 31, 75-85 (2001).
48. Dogrul, A. et al. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 105, 159-168 (2003).
49. 2+ channel blocker, on dorsal horn neuronal responses in rats. Eur. J. Pharmacol. 415, 141-149 (2001).
50. Hord, A.H., Denson, D.D., Chalfoun, A.G. & Azevedo, M.I. The effect of systemic zonisamide (Zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth. Analg. 96, 1700-1706 (2003).
51. 2+ channels. Science 302, 117-119 (2003).
52. Todorovic, S.M., Meyenburg, A. & Jevtovic-Todorovic, V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res. 951, 336-340 (2002).
53. Pietrobon, D. & Striessnig, J. Neurobiology of migraine. Nat. Rev. Neurosci. 4, 386-398 (2003).
54. 2+ channels. Mol. Cell. Neurosci. 14, 255-272 (1999).
55. Mathew, N.T. Antiepileptic drugs in migraine prevention. Headache 41 (suppl. 1), S18-S24 (2001).
56. Brandes, J.L. et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291, 965-973 (2004).
57. Chudnow, R.S., Mimbela, R.A., Owen, D.B. & Roach, E.S. Gabapentin for familial paroxysmal dystonic choreoathetosis. Neurology 49, 1441-1442 (1997).
58. Richter, A. & Löscher, W. Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosis. Eur. J. Pharmacol. 369, 335-338.
59. Fukuda, M., Hashimoto, O., Nagakubo, S. & Hata, A. A family with an atonic variant of paroxysmal kinesigenic choreoathetosis and hypercalcitoninemia. Mov. Disord. 14, 342-344 (1999).
60. Lotze, T. & Jankovic, J. Paroxysmal kinesigenic dyskinesias. Semin. Pediatr. Neurol. 2003 10, 68-79 (2003).
61. Beech, J., Fletcher, J.E., Tripolitis, L. & Lindborgh, S. Effects of phenytoin in two myotonic horses with hyperkalemic periodic paralysis. Muscle Nerve 15, 932-936 (1992).
62. Cannon, S.C. From mutation to myotonia in sodium channel disorders. Neuromuscul. Disord. 7, 241-249 (1997).
63. Caress, J.B. & Walker, F.O. The spectrum of ectopic motor nerve behavior: from fasciculations to neuromyotonia. Neurologist 8, 41-46 (2002).
64. + channel antibodies. Muscle Nerve 27, 757-760 (2003).
65. McGuire, S.A., Tomasovic, J.J. & Ackerman, N. Jr. Hereditary continuous muscle fiber activity. Arch. Neurol. 41, 395-396 (1984).
66. Lubbers, W.J. et al. Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide. J. Neurol. Neurosurg. Psychiatry 59, 400-405 (1995).
67. Kullmann, D.M. The neuronal channelopathies. Brain 125, 1177-1195 (2002).
68. Pahwa, R. & Lyons, K.E. Essential tremor: differential diagnosis and current therapy. Am. J. Med. 115, 134-142 (2003).
69. Connor, G.S. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 59, 132-134 (2002).
70. Praveen, V., Patole, S.K. & Whitehall, J.S. Hyperekplexia in neonates. Postgrad. Med. J. 77, 570-572 (2001).
71. Zhou, L., Chillag, K.L. & Nigro, M.A. Hyperekplexia: a treatable neurogenetic disease. Brain Dev. 24, 669-674 (2002).
72. Muzina, D.J., El-Sayegh, S. & Calabrese, J.R. Antiepileptic drugs in psychiatry-focus on randomized controlled trial. Epilepsy Res. 50, 195-202 (2002).
73. Harwood, A.J. & Agam, G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 66, 179-189 (2003).
74. Manji, H.K. & Duman, R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull. 35, 5-49 (2001).
75. Coyle, J.T. & Duman, RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157-160 (2003).
76. Löscher, W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and models with spontaneous recurrent seizures. Epilepsy Res. 50, 105-123 (2002).
77. Löscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16, 669-694 (2002).
78. Pitkänen, A. Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res. 50, 141-160 (2002).
79. Williams, R.S., Cheng, L., Mudge, A.W. & Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295 (2002).
80. Berridge, M.J., Downes, C.P. & Hanley, M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411-419 (1989).
81. Lubrich, B. & van Calker, D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 21, 519-529 (1999).
82. O'Donnell, T. et al. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res. 880, 84-91 (2000).
83. Vaden, D.L., Ding, D., Peterson, B. & Greenberg, M.L. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 276, 15466-15471 (2001).
84. Lenox, R.H. & Wang, L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol. Psychiatry 8, 135-144 (2003).
85. Li, X., Bijur, G.N. & Jope, R.S. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord. 4, 137-144 (2002).
86. Chen, G., Huang, L.D., Jiang, Y.M. & Manji, H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1330 (1999).
87. Mai, L., Jope, R.S. & Li, X. BDNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J. Neurochem. 82, 75-83 (2002).
88. Yuan, P.X. et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276, 31674-31683 (2001).
89. Einat, H. et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311-7316 (2003).
90. Manji, H.K., Drevets, W.C. & Charney, D.S. The cellular neurobiology of depression. Nat. Med. 7, 541-547 (2001).
91. Winterer, G. & Hermann, W.M. Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry 33, 182-188 (2000).
92. Hosak, L. & Libiger, J. Antiepileptic drugs in schizophrenia: a review. Eur. Psychiatry 17, 371-378 (2002).
93. Göttlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
94. Phiel, C.J. et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741 (2001).
95. Guidotti, A., Pesold, C. & Costa, E. (2000) New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochem. Res. 25, 1207-1218 (2000).
96. Tremolizzo, L. et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. USA 99, 17095-17100 (2002).
97. Akbarian, S. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52, 258-266 (1995).
98. Volk, D.W., Austin, M.C., Pierri, J.N., Sampson, A.R. & Lewis, D.A. Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57, 237-245 (2000).
99. Blum, B.P. & Mann, J.J. The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol. 5, 159-179 (2002).
100. Costa, E., Davis, J., Pesold, C., Tueting, P. & Guidotti, A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr. Opin. Pharmacol. 2, 56-62 (2002).
101. Drake, M.E. et al. Levetiracetam for preventive treatment of migraine. Cephalalgia 21, 373 (2001).
102. Freitag, F.G., Diamond, S. & Solomon, G.D. The prophylaxis of migraine with the GABA-agonist tiagabine: a clinical report. Headache 19, 354 (1999).
103. Gironell, A. et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch. Neurol. 56, 474-480 (1999).
104. Sial, K.A., Malik, A. & Bajwa, Z. Small case series of gabitril (tiagabine) for prophylaxis of chronic daily headache with migrainous features. Arch. Phys. Med. Rehabil. 84, E23 (2003).
105. Krusz, J.C. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21, 373 (2001).
106. Pande, A.C. et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 19, 341-348 (1999).
107. Young, L.T. et al. Gabapentin as an adjunctive treatment in bipolar disorder. J. Affect. Disord. 55, 73-77 (1999).
108. Happe, S., Sauter, C., Klosch, G., Saletu, B. & Zeitlhofer, J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48, 82-86 (2003).
109. Anonymous. Gabapentin (Neurontin) for chronic pain. Med. Lett. Drugs Ther. 46, 29-31 (2004).
110. Johnson, B.A. et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361, 1677-1685 (2003).
111. Myrick, H., Malcolm, R. & Anton, R. The use of antiepileptics in the treatment of addictive disorders. Primary Psychiatry 10, 59-63 (2003).
112. Hoopes, S.P. et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J. Clin. Psych. 64, 1335-1341 (2003).
113. McElroy, S.L. et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry 160, 255-261 (2003).
114. Sarantopoulos, C., McCallum, B., Kwok, W.M. & Hogan, Q. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg. Anesth. Pain Med. 27, 47-57 (2002).